Congrats to Big Pharma on Finding a New Way to Profit Off of HIV Prevention
Gilead, the company that makes Truvada, just got FDA approval for Descovy, another form of PrEP. It costs nearly $1,800 a month without insurance coverage.
Out-Of-Pocket Costs for PrEP Put the HIV Prevention Drug Out Of Reach For Many
It’s getting increasingly difficult for patients to afford Truvada, also known as pre-exposure prophylaxis, because of the drug’s high price and insurance company efforts to restrict patients' use of coupons.